NCT06354660: An ongoing trial by Eli Lilly and Company
This trial is ongoing. It must report results 9 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06354660 |
|---|---|
| Title | A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 10, 2024 |
| Completion date | Jan. 22, 2026 |
| Required reporting date | Jan. 22, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |